Skip to main content
    F

    Fulcrum Therapeutics Inc (FULC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.71
    -0.06 (-1.59%)

    Market Cap: $287.96M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Fulcrum Therapeutics Inc (FULC) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Fulcrum Therapeutics (FULC) to earn -$0.66 per share in the fiscal year ending Dec 31, 2026. Of 5 analysts, 0 rate the stock Buy or Strong Buy, 4 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 3.40, inside the Hold band from 2.5 up to 3.5. Sell and Strong Sell make up 20% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy00.0%
    Hold480.0%
    Sell00.0%
    Strong Sell120.0%
    Consensus
    Hold
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$0.66
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$0.55
    EPS consensus
    Next report
    Feb 22, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.66-$0.81 to -$0.513
    Dec 31, 2027-$0.55-$1.46 to -$0.016

    Quarterly Estimates

    The EPS consensus falls from -$0.10 for the quarter ending Dec 31, 2026 to -$0.36 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.10-$0.30 to -$0.028
    Mar 31, 2027-$0.36-$0.36 to -$0.361

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202611
    Fiscal year ending Dec 31, 202710
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.82.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.66-$0.66-$0.66-$0.76-$0.82N/A
    Fiscal year ending Dec 31, 2027-$0.55-$0.49-$0.49-$0.58-$0.66N/A
    Quarter ending Mar 31, 2027-$0.36-$0.30-$0.28-$0.30-$0.38N/A

    Frequently Asked Questions About FULC

    What is the FULC stock forecast?

    Consensus analyst estimates put Fulcrum Therapeutics's EPS at -$0.66 for the fiscal year ending Dec 31, 2026. The consensus rating from 5 analysts is Hold.

    How do analysts rate FULC stock?

    Of 5 analysts covering Fulcrum Therapeutics, 0 rate it Strong Buy, 0 Buy, 4 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from FULC next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.66, with estimates from -$0.81 to -$0.51 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.55, with estimates from -$1.46 to -$0.01 from 6 analysts.

    How many analysts cover FULC?

    5 analysts rate Fulcrum Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.